Tagged with GEN

Canada Vinod Ramachandran, general manager of Dr. Reddy’s Canadian affiliate, highlights the exciting journey of Dr. Reddy’s in Canada since 2013, the company’s upcoming three specialty product launches, and the goal of Dr. Reddy’s to supply affordable and quality generic medicines. Vinod, you established the Dr. Reddy’s affiliate here four years…

Tunisia Fabrice Barbu, general manager of Servier Tunisia, discusses how Servier wants to build a strong presence in the oncology field in Tunisia and is currently investigating the possibilities of bringing its generics to the market. He also explains how local partners and highly proficient human resources have contributed to the…

Canada Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and the critical importance of Canada possessing a local pharma manufacturing industry. Teva recently announced a new global CEO, Kåre Schultz.…

Ukraine Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces criticism from domestic players. “Healthcare procurement was widely considered as one of the areas most seriously altered by corruption” Tetiana…

Generics With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is facing somewhat of an existential crisis. However, within this difficult market environment, enterprising generics companies are still seeing significant opportunities for growth. “Sometimes it seems as if [non-industry members] believe generic products grow on trees” Jim…

Bulgaria Vladimir Afenliev, chief director business operations, strategic and organizational developments at Sopharma, explains the great success of the strongest Bulgarian pharmaceutical company in the country as well as the upcoming strategies to further grow Sopharma in the region. Sopharma is the most important pharmaceutical group in Bulgaria with activities spanning…

Tunisia Alya El Hedda, GM of Opalia-Recordati in Tunisia, describes the Opalia affiliate’s evolution since the Recordati takeover, her ambitions for the future, and how the company will leverage its production facilities – the largest in Tunisia – to become Recordati’s export hub for the rest of Africa and MENA. Could…

Austria Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern Europe, and the potential ramifications of the European Medicines Agency (EMA) relocating to the city. Could you please start by…

Colombia With the onset of universal public healthcare, new types of foreign actors have been spying fresh opportunities to penetrate the Colombian market. Inward investment from India, in particular, has been increasing year on year, while the number of government sponsored trade delegations promoting the import of India-manufactured generics has multiplied.…

Japan Makoto Suematsu, president of the Japan Agency for Medical Research and Development (AMED), discusses AMED’s successful unification of Japan’s previously disparate systems for medical research funding; the strategic significance of the country’s strong footprint in regenerative medicine and rare diseases; and the organization’s internationalization strategy, propelled by the push to…

Canada Mark Lachovsky, founder and president of Accel Pharma, a Canadian generics company with a unique business model, discusses the inspiring story of how he started and grew the company through challenging times, the important role Accel plays in providing affordable generics drugs to the Canadian population, and his international partnership…

Poland Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and highlights the obstacles that the generics ecosystem faces in light of the new reimbursement act. Furthermore, he provides insights into…